The presence of primary or acquired resistance in melanomas limits the therapeutic efficacy of binimetinib as a monotherapy, as MEK inhibition can lead to the activation of compensatory intracellular signaling pathways, such as the PI3K/AKT/mTOR cascade [34]. This evidence concerns the gene AKT1 and melanoma.